Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.62 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846182 | 0.88 | KMT2A (0.52) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL30117918 | 0.84 | KMT2A (0.66) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL2494411 | 0.84 | KMT2A (0.66) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL29850525 | 0.82 | KMT2A (0.62) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL15304530 | 0.82 | KMT2A (0.62) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL4573298 | 0.81 | ALDH1A1 (0.62) | KMT2ALMNAALDH1A1GPR55HRH4 | |
| SCHEMBL15766183 | 0.78 | KMT2A (0.58) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL4593581 | 0.78 | HRH4 (0.62) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL15766371 | 0.78 | KMT2A (0.61) | KMT2AMEN1RXFP1LMNAALDH1A1 | |
| SCHEMBL4594832 | 0.77 | ALDH1A1 (1.00) | KMT2ALMNAALDH1A1GPR55HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1812113-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | Argenta Discovery Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| EP-1776982-A1 | Pyrimidine compounds as histamine modulators | Argenta Discovery Limited (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1776982-A1 | Pyrimidine compounds as histamine modulators | Argenta Discovery Limited (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1767537-A1 | Pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006050965-A1 | PYRIMIDINE COMPOUNDS AS HISTAMINE MODULATORS | ARGENTA DISCOVERY LTD (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | KMT2A 1030/4885MEN1 4068/4885RXFP1 3438/4885 |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | HRH4, HRH3, HRH2 | KMT2A 441/4885MEN1 2632/4885RXFP1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.